|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-6-8
|
|
pubmed:abstractText |
Angiotensin II type 1 receptor blockers (ARB) are widely recognized to have a vasculoprotective effect. Accumulating data have revealed that calcium antagonists also retard atherosclerosis. We examined the possibility that combination therapy of ARB and calcium antagonists could more effectively prevent atherosclerosis than monotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins E,
http://linkedlifedata.com/resource/pubmed/chemical/Azetidinecarboxylic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydropyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/NADPH Oxidase,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Superoxides,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/azelnidipine,
http://linkedlifedata.com/resource/pubmed/chemical/olmesartan medoxomil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0263-6352
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1383-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15942461-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:15942461-Animals,
pubmed-meshheading:15942461-Apolipoproteins E,
pubmed-meshheading:15942461-Arteriosclerosis,
pubmed-meshheading:15942461-Azetidinecarboxylic Acid,
pubmed-meshheading:15942461-Blotting, Western,
pubmed-meshheading:15942461-Calcium Channel Blockers,
pubmed-meshheading:15942461-Cells, Cultured,
pubmed-meshheading:15942461-Dihydropyridines,
pubmed-meshheading:15942461-Disease Models, Animal,
pubmed-meshheading:15942461-Drug Synergism,
pubmed-meshheading:15942461-Drug Therapy, Combination,
pubmed-meshheading:15942461-Imidazoles,
pubmed-meshheading:15942461-Mice,
pubmed-meshheading:15942461-Mice, Knockout,
pubmed-meshheading:15942461-Muscle, Smooth, Vascular,
pubmed-meshheading:15942461-NADPH Oxidase,
pubmed-meshheading:15942461-Oxidative Stress,
pubmed-meshheading:15942461-Protein-Serine-Threonine Kinases,
pubmed-meshheading:15942461-Proto-Oncogene Proteins,
pubmed-meshheading:15942461-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:15942461-Superoxides,
pubmed-meshheading:15942461-Tetrazoles,
pubmed-meshheading:15942461-Time Factors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
|
|
pubmed:affiliation |
Department of Molecular and Cellular Biology, Division of Medical Biochemistry and Cardiovascular Biology, Ehime University School of Medicine, Ehime, Japan.
|
|
pubmed:publicationType |
Journal Article
|
